Work

Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin; R) on the pharmacokinetics (PK) of Cbz.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2560

Authors: Alain C. Mita, Albert C. Lockhart, James Lloyd Wade, John Charles Morris, Olivier Rixe, Jean-François Dedieu, Claudine Wack, Laurent Kassalow, John Sarantopoulos

Institutions: Cedars-Sinai Medical Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, University of Cincinnati, Augusta University, Sanofi (France), Sanofi (United States), The University of Texas at San Antonio Health Science Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603545084

Cites:

Cited by: 1

Related to: 10